Jade Biosciences
Jade Biosciences is a biotech company focused on developing therapies for autoimmune diseases. It is currently advancing multiple antibody candidates through clinical and preclinical stages. The company emphasizes innovative drug development and collaboration across scientific and operational teams.
Jade Biosciences is a clinical-stage biotechnology company on a mission to transform the standard of care for patients with autoimmune diseases. The company develops a pipeline of potentially best-in-class therapies built on discovery-stage assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. Its lead candidate, JADE101, is designed to inhibit the cytokine APRIL and is being developed for the treatment of immunoglobulin A nephropathy (IgAN).
Zacks Research Downgrades Jade Biosciences (NASDAQ:JBIO) to Strong Sell
11 hours ago
Guggenheim raises Jade Biosciences stock price target on pipeline progress
1 day ago
Jade Biosciences Touts “Best-in-Class” Autoimmune Antibodies, JADE101 Phase 1 Readout Nears
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Jade Biosciences.
159% above the average for this role
Jade Biosciences Announces $135 Million Private Placement
Oct 7, 2025